277 related articles for article (PubMed ID: 38116007)
1. Separation of GVL from GVHD -location, location, location.
Teshima T; Hashimoto D
Front Immunol; 2023; 14():1296663. PubMed ID: 38116007
[TBL] [Abstract][Full Text] [Related]
2. [Immune tolerance induced by cytokines in allogeneic hematopoietic stem cell transplantation].
Chang YJ; Huang XJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Apr; 41(2):208-11. PubMed ID: 19377632
[TBL] [Abstract][Full Text] [Related]
3. Retention of Donor T Cells in Lymphohematopoietic Tissue and Augmentation of Tissue PD-L1 Protection for Prevention of GVHD While Preserving GVL Activity.
Song Q; Nasri U; Nakamura R; Martin PJ; Zeng D
Front Immunol; 2022; 13():907673. PubMed ID: 35677056
[TBL] [Abstract][Full Text] [Related]
4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
5. Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL and GVHD in Allo-HSCT.
Mammadli M; Huang W; Harris R; Sultana A; Cheng Y; Tong W; Pu J; Gentile T; Dsouza S; Yang Q; Bah A; August A; Karimi M
Front Immunol; 2020; 11():593863. PubMed ID: 33324410
[TBL] [Abstract][Full Text] [Related]
6. Ceramide synthase 6 impacts T-cell allogeneic response and graft-versus-host disease through regulating N-RAS/ERK pathway.
Sofi MH; Tian L; Schutt S; Khan I; Choi HJ; Wu Y; Bastian D; Ticer T; Kassir MF; Atilgan FC; Kim J; Sui X; Zivkovic A; Mehrotra S; O'Bryan JP; Stark H; Martin PJ; Ogretmen B; Yu XZ
Leukemia; 2022 Jul; 36(7):1907-1915. PubMed ID: 35513703
[TBL] [Abstract][Full Text] [Related]
7. Prevention of GVHD without losing GVL effect: windows of opportunity.
Zhang P; Chen BJ; Chao NJ
Immunol Res; 2011 Apr; 49(1-3):49-55. PubMed ID: 21136200
[TBL] [Abstract][Full Text] [Related]
8. Ikaros deficiency in host hematopoietic cells separates GVL from GVHD after experimental allogeneic hematopoietic cell transplantation.
Toubai T; Guoqing H; Rossi C; Mathewson N; Oravecz-Wilson K; Cummings E; Wu J; Sun Y; Choi S; Reddy P
Oncoimmunology; 2015 Jul; 4(7):e1016699. PubMed ID: 26140241
[TBL] [Abstract][Full Text] [Related]
9. The impact of regulatory T cells on the graft-versus-leukemia effect.
Pacini CP; Soares MVD; Lacerda JF
Front Immunol; 2024; 15():1339318. PubMed ID: 38711496
[TBL] [Abstract][Full Text] [Related]
10. New developments in allotransplant immunology.
Barrett AJ; Rezvani K; Solomon S; Dickinson AM; Wang XN; Stark G; Cullup H; Jarvis M; Middleton PG; Chao N
Hematology Am Soc Hematol Educ Program; 2003; ():350-71. PubMed ID: 14633790
[TBL] [Abstract][Full Text] [Related]
11. Metabolic Targets for Improvement of Allogeneic Hematopoietic Stem Cell Transplantation and Graft-vs.-Host Disease.
Tijaro-Ovalle NM; Karantanos T; Wang HT; Boussiotis VA
Front Immunol; 2019; 10():295. PubMed ID: 30891031
[TBL] [Abstract][Full Text] [Related]
12. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD3 preconditioning separates GVL from GVHD via modulating host dendritic cell and donor T-cell migration in recipients conditioned with TBI.
Li N; Chen Y; He W; Yi T; Zhao D; Zhang C; Lin CL; Todorov I; Kandeel F; Forman S; Zeng D
Blood; 2009 Jan; 113(4):953-62. PubMed ID: 18922852
[TBL] [Abstract][Full Text] [Related]
14. Targeting the Complement Alternative Pathway Permits Graft Versus Leukemia Activity while Preventing Graft Versus Host Disease.
Nguyen H; Alawieh A; Bastian D; Kuril S; Dai M; Daenthanasanmak A; Zhang M; Iamsawat S; Schutt SD; Wu Y; Sleiman MM; Shetty A; Atkinson C; Sun S; Varela JC; Tomlinson S; Yu XZ
Clin Cancer Res; 2020 Jul; 26(13):3481-3490. PubMed ID: 31919135
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic inhibition of PKCα and PKCθ prevents GVHD while preserving GVL activity in mice.
Haarberg KM; Li J; Heinrichs J; Wang D; Liu C; Bronk CC; Kaosaard K; Owyang AM; Holland S; Masuda E; Tso K; Blazar BR; Anasetti C; Beg AA; Yu XZ
Blood; 2013 Oct; 122(14):2500-11. PubMed ID: 23908466
[TBL] [Abstract][Full Text] [Related]
16. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration.
Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H
Front Immunol; 2021; 12():785774. PubMed ID: 34987512
[TBL] [Abstract][Full Text] [Related]
17. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
Fowler DH; Gress RE
Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
[TBL] [Abstract][Full Text] [Related]
18. Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice.
Asakura S; Hashimoto D; Takashima S; Sugiyama H; Maeda Y; Akashi K; Tanimoto M; Teshima T
J Clin Invest; 2010 Jul; 120(7):2370-8. PubMed ID: 20530875
[TBL] [Abstract][Full Text] [Related]
19. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.
Chang YJ; Zhao XY; Huang XJ
Front Immunol; 2018; 9():3041. PubMed ID: 30619371
[TBL] [Abstract][Full Text] [Related]
20. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
